Work

MPN-384 A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement

Year: 2024

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(24)01430-7

Authors: Alessandro M. Vannucchi, Jay L. Patel, William E. Shomali, Tracy I. George, Andreas Reiter, Alessandro Rambaldi, Stephen Oh, Kensuke Usuki, Claire N. Harrison, Maria Luisa Veronese, Aidan Gilmartin, Huiling Zhen, Srdan Verstovsek, Natalia Oliveira, Jason Gotlib, Jean-Jacques Kiladjian

Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Utah, ARUP Laboratories (United States), Stanford Cancer Institute, Stanford University, Heidelberg University, University of Milan, Ospedale Papa Giovanni XXIII, Washington University in St. Louis, NTT Medical Center, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, Incyte (United States), The University of Texas MD Anderson Cancer Center, Hôpital Saint-Louis

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401876338

Cites:

Cited by: 4

Related to: 10